Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06716645 · ClinicalTrials.gov registry record · Phase 4
A Clinical Evidence Study Evaluating Quality of Life Parameters Following Treatment With Robitussin
A Phase 4 study of Cough and Common Cold, sponsored by HALEON.
- Completed
- Registry status
- Phase 4
- Development phase
- 244
- Enrollment target
- 1
- Study location
NCT06716645 is a Phase 4 study of Cough and Common Cold that has completed, run by HALEON. The registered enrollment target is 244 participants, above the 202-participant average among 12 other Cough trials with a reported enrollment target (21% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06716645, a Phase 4 study of Cough and Common Cold, has completed, sponsored by HALEON.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 244 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this Real-World Evidence study is to generate real world data from participants with cough associated with the common cold, evaluating the effects in two arms with commercially available cough syrups on health-related quality of life (QoL). Arm 1 includes one cough syrup (which can be used day or night) and Arm 2 includes the daytime cough syrup and a nighttime cough syrup.
Conditions Studied
Interventions
- DRUG Robitussin Maximum Strength Cough and Chest Congestion DM
- DRUG Robitussin Maximum Strength Nighttime Cough DM
Study Locations (1)
New York
- Lindus Health Limited - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 244 participants |
| Start Date | 2024-12-04 |
| Est. Completion | 2025-02-14 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06716645
The ClinicalTrials.gov registry entry for NCT06716645 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 244 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 202-participant average among 12 other Cough trials with a reported enrollment target (21% higher). The listed sponsor is HALEON, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cough appearing as the primary indexed condition, and to 2 interventions - of which Robitussin Maximum Strength Cough and Chest Congestion DM is the first listed.
NCT06716645 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06716645 about?
NCT06716645 is a clinical study titled "A Clinical Evidence Study Evaluating Quality of Life Parameters Following Treatment With Robitussin". The purpose of this Real-World Evidence study is to generate real world data from participants with cough associated with the common cold, evaluating the effects in two arms with commercially available cough syrups on health-related quality of life (QoL). Arm 1 includes one cough syrup (which can be...
What is the current status of trial NCT06716645?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 244 participants. The study started on 2024-12-04. Estimated completion is 2025-02-14.
What conditions does trial NCT06716645 study?
This clinical trial studies the following conditions: Cough, Common Cold.
What interventions are being tested in trial NCT06716645?
The interventions under investigation include: Robitussin Maximum Strength Cough and Chest Congestion DM (DRUG), Robitussin Maximum Strength Nighttime Cough DM (DRUG).
Who is sponsoring clinical trial NCT06716645?
This trial is sponsored by HALEON, which has 34 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06716645 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cough
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Mechanism Versus PPI Trial
RECRUITING · Phase 4
-
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
RECRUITING · Phase 3
-
Office-Based Superior Laryngeal Nerve Block for Treatment of Neurogenic Cough
RECRUITING
-
Stimulation of the Larynx to Treat Unexplained Chronic Cough
RECRUITING · NA
-
Work of Breathing Assessment in Triage Scale
ACTIVE NOT RECRUITING
-
A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.